Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05106725 · ClinicalTrials.gov registry record
Wearable Devices and Biomarkers Project (Healthiomics)
A clinical trial of Brain Cancer and Neurological Disorder, sponsored by CureScience.
- Recruiting
- Registry status
- 3,500
- Enrollment target
- 1
- Study location
NCT05106725: Recruiting study of Brain Cancer and Neurological Disorder, sponsored by CureScience.
NCT05106725 is a study of Brain Cancer and Neurological Disorder that is actively recruiting participants, run by CureScience. The registered enrollment target is 3,500 participants, above the 433-participant average among 47 other Brain Cancer trials with a reported enrollment target (708% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05106725, a study of Brain Cancer and Neurological Disorder, is actively recruiting participants, sponsored by CureScience.
- RECRUITING
- Registry status
- 3,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect clinical data, biological specimens (e.g., blood, tumor, cerebrospinal fluid, urine sample, etc.), and digital health data from patients with tumors, cancer and/or neurological disorders in order to perform research studies that could advance patient care. By collecting these specimens, the investigators plan to create and maintain a biorepository to make data and specimens available to collaborating investigators performing research to discover predictive biomarkers, patterns of care, and personalized treatments that could directly improve the care of our patients through focused proof-of-concept clinical trials.
Conditions Studied
Study Locations (1)
California
- CureScience Institute - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,500 participants |
| Start Date | 2021-10-11 |
| Est. Completion | 2025-12-31 |
What NCT05106725 shows while recruiting
NCT05106725 is an observational study that tracks outcomes without assigning an intervention. Its 3,500 participants enrollment target places it among the larger protocols in the corpus, above the 433-participant average among 47 other Brain Cancer trials with a reported enrollment target (708% higher).
The record links to 3 conditions, with Brain Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05106725 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05106725 about?
NCT05106725 is a clinical study titled "Wearable Devices and Biomarkers Project (Healthiomics)". The purpose of this study is to collect clinical data, biological specimens (e.g., blood, tumor, cerebrospinal fluid, urine sample, etc.), and digital health data from patients with tumors, cancer and/or neurological disorders in order to perform research studies that could advance patient care. By ...
What is the current status of trial NCT05106725?
This trial is currently recruiting. The enrollment target is 3,500 participants. The study started on 2021-10-11. Estimated completion is 2025-12-31.
What conditions does trial NCT05106725 study?
This clinical trial studies the following conditions: Brain Cancer, Neurological Disorder, Neurological Cancer.
Who is sponsoring clinical trial NCT05106725?
This trial is sponsored by CureScience, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05106725 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05106725's enrollment target sits among peer trials
3,500 3rd of 47 higher than 45 of 47 other Brain Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI